ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $135.46 million. The enterprise value is $8.27 million.
| Market Cap | 135.46M |
| Enterprise Value | 8.27M |
Important Dates
The next estimated earnings date is Friday, November 6, 2026, before market open.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALXO has 138.28 million shares outstanding. The number of shares has increased by 61.42% in one year.
| Current Share Class | 138.28M |
| Shares Outstanding | 138.28M |
| Shares Change (YoY) | +61.42% |
| Shares Change (QoQ) | +29.71% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 58.49% |
| Float | 94.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.99 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.71, with a Debt / Equity ratio of 0.08.
| Current Ratio | 9.71 |
| Quick Ratio | 9.43 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.84 |
Financial Efficiency
Return on equity (ROE) is -80.65% and return on invested capital (ROIC) is -45.42%.
| Return on Equity (ROE) | -80.65% |
| Return on Assets (ROA) | -40.40% |
| Return on Invested Capital (ROIC) | -45.42% |
| Return on Capital Employed (ROCE) | -56.69% |
| Weighted Average Cost of Capital (WACC) | 7.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.69M |
| Employee Count | 48 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.27% in the last 52 weeks. The beta is 0.48, so ALXO's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -40.27% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 1.83 |
| Relative Strength Index (RSI) | 25.24 |
| Average Volume (20 Days) | 1,435,859 |
Short Selling Information
The latest short interest is 5.67 million, so 4.10% of the outstanding shares have been sold short.
| Short Interest | 5.67M |
| Short Previous Month | 6.27M |
| Short % of Shares Out | 4.10% |
| Short % of Float | 5.99% |
| Short Ratio (days to cover) | 4.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -82.79M |
| Pretax Income | -80.89M |
| Net Income | -80.89M |
| EBITDA | -82.30M |
| EBIT | -82.79M |
| Earnings Per Share (EPS) | -$0.93 |
Balance Sheet
The company has $138.23 million in cash and $11.04 million in debt, with a net cash position of $127.19 million or $0.92 per share.
| Cash & Cash Equivalents | 138.23M |
| Total Debt | 11.04M |
| Net Cash | 127.19M |
| Net Cash Per Share | $0.92 |
| Equity (Book Value) | 136.19M |
| Book Value Per Share | 0.99 |
| Working Capital | 128.68M |
Cash Flow
In the last 12 months, operating cash flow was -$70.78 million and capital expenditures -$172,000, giving a free cash flow of -$70.95 million.
| Operating Cash Flow | -70.78M |
| Capital Expenditures | -172,000 |
| Depreciation & Amortization | 495,000 |
| Net Borrowing | 6.03M |
| Free Cash Flow | -70.95M |
| FCF Per Share | -$0.51 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALXO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -61.42% |
| Shareholder Yield | -61.42% |
| Earnings Yield | -59.72% |
| FCF Yield | -52.38% |
Analyst Forecast
The average price target for ALXO is $4.60, which is 369.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.60 |
| Price Target Difference | 369.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |